Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14031335 | 1.00 | KMT2A (0.56) | KMT2AMEN1POLBGRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL10888722 | 0.97 | KMT2A (0.54) | KMT2AMEN1POLBGRIN1GRIN2B | |
| SCHEMBL14339598 | 0.86 | GRIN2B (0.56) | KMT2AMEN1POLBGRIN2BCYP2D6 | |
| SCHEMBL18938347 | 0.78 | KMT2A (0.61) | KMT2AMEN1POLBGRIN1GRIN2B | |
| SCHEMBL14393378 | 0.77 | KDM1A (0.50) | KMT2AMEN1NPSR1CYP2D6HIF1A | |
| SCHEMBL15653057 | 0.77 | MASP2 (0.48) | KMT2AMEN1POLBCYP2D6HIF1A | |
| SCHEMBL25914317 | 0.77 | CYP2D6 (0.55) | KMT2AMEN1POLBCYP2D6HIF1A | |
| Benzamidoxime SCHEMBL30242 | 0.76 | KMT2A (0.58) | KMT2AMEN1POLBGRIN1GRIN2B | |
| SCHEMBL22872296 | 0.76 | KMT2A (0.58) | KMT2AMEN1POLBGRIN1GRIN2B | |
| SCHEMBL11323612 | 0.76 | KMT2A (0.65) | KMT2AMEN1POLBGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| CN-110272395-A | A kind of method of the asymmetric polysubstituted amino -1,3,5- compound in triazine class of photocatalysis preparation | 赣南师范大学 | 2019-09-24 | — | — | CN | disclosed |
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-02-22 | — | — | US | disclosed |
| US-9688672-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9434719-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2016-09-06 | — | — | US | disclosed |
| EP-2970240-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| EP-2906553-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20150152093-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| WO-2008152149-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008110891-A2 | NEW HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED, (IN) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221103-A1 | New heterocyclic compounds | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2008-09-11 | — | — | US | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| EP-0025321-B1 | COMPOSITION CONTAINING S-SULFONATED IMMUNOGLOBULIN AND AGGREGATION PREVENTING OR AGGREGATE DISSOCIATING AGENT THEREFOR, AND PROCESSES FOR PREPARING COMPOSITIONS CONTAINING HIGH PROPORTIONS OF MONOMERIC S-SULFONATED IMMUNOGLOBULIN | TEIJIN LIMITED (JP) | 1984-03-21 | — | — | EP | disclosed |
| EP-0001965-B1 | PROCESS FOR THE PREPARATION OF FOAMED MATERIALS | BAYER AG (DE) | 1982-12-15 | — | — | EP | disclosed |
| US-4362661-A | BASIC AMINO ACID SALT TO PREVENT AGGREGATION | TEIJIN LIMITED (JP) | 1982-12-07 | — | — | US | disclosed |
| US-4360457-A | AMINO ACID SALT | TEIJIN LIMITED (JP) | 1982-11-23 | — | — | US | disclosed |
| EP-0025321-A2 | Composition containing S-sulfonated immunoglobulin and aggregation preventing or aggregate dissociating agent therefor, and processes for preparing compositions containing high proportions of monomeric S-sulfonated immunoglobulin | TEIJIN LIMITED (JP) | 1981-03-18 | — | — | EP | disclosed |
| EP-0025275-A2 | Immunoglobulin-containing composition containing an aggregation preventing or aggregate dissociating agent for the immunoglobulin, and process for preparation thereof | TEIJIN LIMITED (JP) | 1981-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | KMT2A 78/4885MEN1 2398/4885POLB 572/4885 |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | KMT2A 78/4885MEN1 2398/4885POLB 572/4885 |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | KMT2A 4651/4885MEN1 3674/4885POLB 3463/4885 |
| US-20150152093-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | KMT2A 78/4885MEN1 2398/4885POLB 572/4885 |
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | IDH1, IDH3B, IDH3A | KMT2A 78/4885MEN1 2398/4885POLB 572/4885 |
| US-20080221103-A1 | New heterocyclic compounds | LOXL4, CXCR4, LTC4S | KMT2A 4045/4885MEN1 1470/4885POLB 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.